32.97
price up icon0.92%   0.30
after-market Dopo l'orario di chiusura: 32.97
loading
Precedente Chiudi:
$32.67
Aprire:
$32.82
Volume 24 ore:
279.18K
Relative Volume:
0.49
Capitalizzazione di mercato:
$1.85B
Reddito:
$651.97M
Utile/perdita netta:
$59.71M
Rapporto P/E:
30.82
EPS:
1.0696
Flusso di cassa netto:
$172.03M
1 W Prestazione:
-1.64%
1M Prestazione:
+3.06%
6M Prestazione:
-14.67%
1 anno Prestazione:
+10.27%
Intervallo 1D:
Value
$32.76
$33.02
Intervallo di 1 settimana:
Value
$32.20
$34.40
Portata 52W:
Value
$27.05
$40.28

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Name
Nome
Supernus Pharmaceuticals Inc
Name
Telefono
301-838-2500
Name
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Name
Dipendente
674
Name
Cinguettio
@Supernus_Pharma
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
SUPN's Discussions on Twitter

Confronta SUPN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
SUPN
Supernus Pharmaceuticals Inc
32.97 1.83B 651.97M 59.71M 172.03M 1.0696
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
153.45 67.31B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.74 45.95B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.75 43.35B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.58 18.68B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
305.61 13.44B 2.99B 1.21B 1.13B 25.06

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-19 Downgrade Cantor Fitzgerald Overweight → Neutral
2025-01-06 Iniziato Cantor Fitzgerald Overweight
2024-09-11 Downgrade Piper Sandler Overweight → Neutral
2023-01-03 Ripresa Jefferies Buy
2021-12-01 Ripresa Jefferies Buy
2021-04-13 Aggiornamento Jefferies Hold → Buy
2020-06-16 Aggiornamento Piper Sandler Neutral → Overweight
2020-06-15 Ripresa Jefferies Hold
2019-11-08 Downgrade Berenberg Buy → Hold
2019-11-07 Downgrade Stifel Buy → Hold
2019-11-06 Downgrade Jefferies Buy → Hold
2018-11-12 Reiterato B. Riley FBR Buy
2018-01-18 Reiterato B. Riley FBR, Inc. Buy
2017-12-28 Reiterato B. Riley FBR, Inc. Buy
2017-12-04 Aggiornamento Janney Neutral → Buy
2017-11-08 Aggiornamento Stifel Hold → Buy
2017-10-19 Iniziato FBR & Co. Buy
2017-09-19 Downgrade Stifel Buy → Hold
2017-07-17 Downgrade Piper Jaffray Overweight → Neutral
2017-07-14 Iniziato Janney Neutral
2017-06-01 Aggiornamento Piper Jaffray Neutral → Overweight
2016-07-18 Downgrade Northland Capital Outperform → Market Perform
2016-07-18 Downgrade Piper Jaffray Overweight → Neutral
2016-02-08 Aggiornamento Jefferies Hold → Buy
2015-11-05 Reiterato Northland Capital Outperform
2015-10-28 Iniziato Northland Capital Outperform
Mostra tutto

Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie

pulisher
Jul 23, 2025

Is Supernus Pharmaceuticals Inc. a good long term investmentExtraordinary performance - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Supernus Pharmaceuticals Inc. Stock Analysis and ForecastStrong return on investment - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price - simplywall.st

Jul 23, 2025
pulisher
Jul 23, 2025

Published on: 2025-07-23 12:28:32 - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Supernus Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 5 - Quiver Quantitative

Jul 22, 2025
pulisher
Jul 22, 2025

Supernus Pharmaceuticals to Announce Second Quarter 2025 - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025 - Yahoo.co

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Supernus Pharmaceuticals Inc. stockTremendous portfolio expansion - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Supernus Pharmaceuticals Inc. stock priceExtraordinary performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

Supernus Pharmaceuticals Faces 3.2% Share Decline: Sector Challenges ImpactNews and Statistics - IndexBox

Jul 19, 2025
pulisher
Jul 18, 2025

(SUPN) Investment Report - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 18, 2025

Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

Is Supernus Pharmaceuticals Inc. stock a growth or value playQuick Profit Idea Stream - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Holdings Lowered by Teacher Retirement System of Texas - Defense World

Jul 17, 2025
pulisher
Jul 15, 2025

Why Supernus Pharmaceuticals Inc. stock attracts strong analyst attentionTop Rated Trade Entries - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Supernus Pharmaceuticals Inc. stock performs during market volatilityStrong Buy Recommendations - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Supernus Pharmaceuticals Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Principal Financial Group Inc. Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World

Jul 15, 2025
pulisher
Jul 11, 2025

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Amalgamated Bank - Defense World

Jul 11, 2025
pulisher
Jul 10, 2025

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Allspring Global Investments Holdings LLC - Defense World

Jul 10, 2025
pulisher
Jul 08, 2025

When the Price of (SUPN) Talks, People Listen - news.stocktradersdaily.com

Jul 08, 2025
pulisher
Jul 02, 2025

Supernus Pharmaceuticals to Acquire Sage Therapeutics in Transaction Valued Up to $795 Million - Global Legal Chronicle

Jul 02, 2025
pulisher
Jun 30, 2025

Busy Philipps, Jay Glazer highlight ADHD experiences in Supernus’ campaigns - Medical Marketing and Media

Jun 30, 2025
pulisher
Jun 27, 2025

Supernus Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance

Jun 27, 2025
pulisher
Jun 23, 2025

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five years - Yahoo Finance

Jun 23, 2025
pulisher
Jun 18, 2025

Supernus to acquire Sage Therapeutics stock for $8.50 per share By Investing.com - Investing.com UK

Jun 18, 2025
pulisher
Jun 18, 2025

Supernus to acquire depression drugmaker Sage - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Apomorphine Delivery Device Market Set to Witness Significant - openPR.com

Jun 18, 2025
pulisher
Jun 17, 2025

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Supernus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Are Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - simplywall.st

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE to Be Acquired by Supernus Pharmaceuticals | SAGE Stock New - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Trading (SUPN) With Integrated Risk Controls - news.stocktradersdaily.com

Jun 17, 2025
pulisher
Jun 16, 2025

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - whbl.com

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals picks up embattled Sage Therapeutics - Mugglehead Magazine

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Secures Sage With CVR-Supported Deal - insights.citeline.com

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to Acquire Sage Therapeutics in $795M Deal - USA Herald

Jun 16, 2025
pulisher
Jun 16, 2025

Saul Ewing-Led Supernus Inks Up To $795M Brain Health Deal - Law360

Jun 16, 2025
pulisher
Jun 16, 2025

Deals of the day-Mergers and acquisitions - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to acquire Sage Therapeutics for up to $795 million By Investing.com - Investing.com South Africa

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus enters depression drug market with up to $795 million Sage deal | Business Information & News | FE - Westlaw Today

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes (NASDAQ:SUPN) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus’ $795 million bid sufficient for Sage - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's

Jun 16, 2025

Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$73.31
price up icon 1.34%
$15.02
price up icon 0.60%
$9.37
price up icon 1.41%
drug_manufacturers_specialty_generic RDY
$14.60
price up icon 1.32%
$133.66
price up icon 0.69%
$305.61
price up icon 2.59%
Capitalizzazione:     |  Volume (24 ore):